Jennifer W Mack1, Kun Chen, Francis P Boscoe, Foster C Gesten, Patrick J Roohan, Maria J Schymura, Deborah Schrag. 1. *Department of Pediatric Oncology †The Division of Population Sciences' Center for Outcomes and Policy Research, Dana-Farber Cancer Institute ‡Division of Pediatric Hematology/Oncology, Children's Hospital, Boston, MA §New York State Department of Health, State Cancer Registry ∥New York State Department of Health, Office of Quality and Patient Safety, Albany, NY ¶Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Abstract
BACKGROUND: Little is known about the care that adolescent and young adult (AYA) cancer patients receive at the end of life (EOL). OBJECTIVE: To evaluate use of intensive measures and hospice and location of death of AYA cancer patients insured by Medicaid in New York State. DESIGN: Using linked patient-level data from the New York State Cancer Registry and state Medicaid program, we identified 705 Medicaid patients who were diagnosed with cancer between the ages of 15 and 29 in the years 2004-2011, who subsequently died, and who were continuously enrolled in Medicaid in the last 60 days of life. We evaluated use of intensive EOL measures (chemotherapy within 14 d of death; intensive care unit care, >1 emergency room visit, and hospitalizations in the last 30 d of life), hospice use, and location of death (inpatient hospice, long-term care facility, acute care facility, home with hospice, home without hospice). RESULTS: 75% of AYA Medicaid decedents used at least 1 aspect of intensive EOL care. 38% received chemotherapy in the last 2 weeks of life; 21% received intensive care unit care, 44% had >1 emergency room visit, and 64% were hospitalized in the last month of life. Only 23% used hospice. 65% of patients died in acute care settings, including the inpatient hospital or emergency room. CONCLUSIONS: Given the high rates of intensive measures and low utilization of hospice at the EOL among AYA Medicaid enrollees, opportunities to maximize the quality of EOL care in this high-risk group should be prioritized.
BACKGROUND: Little is known about the care that adolescent and young adult (AYA) cancerpatients receive at the end of life (EOL). OBJECTIVE: To evaluate use of intensive measures and hospice and location of death of AYA cancerpatients insured by Medicaid in New York State. DESIGN: Using linked patient-level data from the New York State Cancer Registry and state Medicaid program, we identified 705 Medicaid patients who were diagnosed with cancer between the ages of 15 and 29 in the years 2004-2011, who subsequently died, and who were continuously enrolled in Medicaid in the last 60 days of life. We evaluated use of intensive EOL measures (chemotherapy within 14 d of death; intensive care unit care, >1 emergency room visit, and hospitalizations in the last 30 d of life), hospice use, and location of death (inpatient hospice, long-term care facility, acute care facility, home with hospice, home without hospice). RESULTS: 75% of AYA Medicaid decedents used at least 1 aspect of intensive EOL care. 38% received chemotherapy in the last 2 weeks of life; 21% received intensive care unit care, 44% had >1 emergency room visit, and 64% were hospitalized in the last month of life. Only 23% used hospice. 65% of patients died in acute care settings, including the inpatient hospital or emergency room. CONCLUSIONS: Given the high rates of intensive measures and low utilization of hospice at the EOL among AYA Medicaid enrollees, opportunities to maximize the quality of EOL care in this high-risk group should be prioritized.
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; Jeffrey M Souza; Jane C Weeks; Susan D Block; Eva Grunfeld; John Z Ayanian Journal: Int J Qual Health Care Date: 2005-06-28 Impact factor: 2.038
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Richard Brumley; Susan Enguidanos; Paula Jamison; Rae Seitz; Nora Morgenstern; Sherry Saito; Jan McIlwane; Kristine Hillary; Jorge Gonzalez Journal: J Am Geriatr Soc Date: 2007-07 Impact factor: 5.562
Authors: Katherine B Curtin; Anne E Watson; Jichuan Wang; Obianuju C Okonkwo; Maureen E Lyon Journal: Contemp Clin Trials Date: 2017-08-24 Impact factor: 2.226
Authors: J M Snaman; A C Talleur; J Lu; D R Levine; E C Kaye; A Sykes; Z Lu; B M Triplett; J N Baker Journal: Bone Marrow Transplant Date: 2017-11-13 Impact factor: 5.483
Authors: Eric J Roeland; Lisa C Lindley; Stephanie Gilbertson-White; Seyedehtanaz Saeidzadeh; Erin R Currie; Sarah Friedman; Marie Bakitas; Jennifer W Mack Journal: Cancer Date: 2019-11-14 Impact factor: 6.860
Authors: K Robin Yabroff; Katherine Reeder-Hayes; Jingxuan Zhao; Michael T Halpern; Ana Maria Lopez; Leon Bernal-Mizrachi; Anderson B Collier; Joan Neuner; Jonathan Phillips; William Blackstock; Manali Patel Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Emily E Johnston; Lori Muffly; Elysia Alvarez; Olga Saynina; Lee M Sanders; Smita Bhatia; Lisa J Chamberlain Journal: J Clin Oncol Date: 2018-09-05 Impact factor: 44.544